tumour surpressors and oncogenes Flashcards

1
Q

initial and later hallmarks of cancer

A

evade growth suppression and apoptosis rapid replication metastasis angiogenesis LATER- inflammation, avoiding immunity, mutations, and affecting cellular energetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

later hallmarks of cancer

A

inflammation, avoiding immunity, mutations, and affecting cellular energetics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

what are protooncogenes and how do they become oncogenes

A

involved in cell growth/proliferation a SINGLE mutation produces an oncogene= cell division no longer in control

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

how oncogenes are activated

A

point mutation/deletion in protooncogene produces abberant (unusual) protein, or overproduces protein can lead to chromosomal translocation OR INSERTIONAL MUTAGENESIS= enhances normal protein levels OR fusion protein eg Philadelphia chromosome

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

DIAGRAM 2 types of receptors and downstream signalling with examples

A

tyrosine kinase= adapter proteins=kinase cascade G protein coupled- goes immediately to Ras Raf cascade met, neu affected at TK receptor, ras/raf affected in cascade myc, fos, jun affected at transcription

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

what happens in mutant RAS

A

normally, when GTP converted to GDP , RAS switched off in mutant tase, GTP can’t be dephosphorylated

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

example of tyrosine kinase mutation (oncogene)

A

SRC- C terminal deletion (thing that controls it)- occurs in breast/colon

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

example of T.F mutations (oncogene)

A

MYC (Burkitt’s lymphoma) and Jun (lung)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

example of G protein mutations and location in cell

A

Ha Ras (bladder) and Ki Ras (colon)- both G proteins and TK are cytoplasmic, T.F’s are nuclear

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

what are TMS and how many mutations needed

A

they CONTROL cell proliferation- needs to be 2 mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

knudsons 2 hit hypothesis

A

sporadic cancer= 2 acquired mutations needed hereditary cancer= 1 inherited+ 1 acquired mutation ie HAPLOINSUFFICIENCY

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

features of inherited cancer susceptibility ie inherited TMS mutation

A

family history of cancers early age onset tumours in pair organs eg breast tumours in different organs at same time eg P53 mutations

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

retinoblastoma and gene involved

A

malignancy of retinal cells- involves RB1 TMS gene (regulates cell cycle)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

classes of TMS and common feature of all

A

regulate cell cycle, or repair proteins, or cell death regulators they all supress NEOPLASTIC PHENOTYPE (stop cells from going wrong)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

cell cycle regulators and cancers

A

P53 (many) and BRCA1 (breast/prostate)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

mutation of p53

A

even though its TMS, only ONE mutation needed

17
Q

APC TMS- what is it, and effect of mutation

A

this gene involved in cell adhesion (regulates B catenin) + signalling, so deletion in gene causes many benign polyps in colon aka FAP, which is likely to become malignant

18
Q

development of colorectal cancer

A

epithelium normal, then APC mutation= hyperproliferative epithelium Kras mutation= adenoma (benign), and late p53 mutation= carcinoma

19
Q

TMS VS oncogene- types of mutations, heritability, specificity and type of tumour

A

TMS deletions vs translocations/joint mutation sometimes inherited vs rare tumour specific (ie often affects a certain region) vs broad tissue specificity solid tumours vs leukemia/lymphoma